0000904454-24-000187.txt : 20240228
0000904454-24-000187.hdr.sgml : 20240228
20240228161748
ACCESSION NUMBER: 0000904454-24-000187
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240226
FILED AS OF DATE: 20240228
DATE AS OF CHANGE: 20240228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kapusta Matthew C
CENTRAL INDEX KEY: 0001536290
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36294
FILM NUMBER: 24695655
MAIL ADDRESS:
STREET 1: 7358 MCVAY ROAD
CITY: GERMANTOWN
STATE: TN
ZIP: 38138
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: uniQure N.V.
CENTRAL INDEX KEY: 0001590560
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
BUSINESS PHONE: 1-339-970-7000
MAIL ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
FORMER COMPANY:
FORMER CONFORMED NAME: uniQure B.V.
DATE OF NAME CHANGE: 20131030
4
1
edgar.xml
PRIMARY DOCUMENT
X0508
4
2024-02-26
0
0001590560
uniQure N.V.
QURE
0001536290
Kapusta Matthew C
C/O UNIQURE N.V.
PAASHEUVELWEG 25A
AMSTERDAM
P7
11058BP
NETHERLANDS
1
1
0
0
CEO, Managing Director
0
Ordinary Shares
2024-02-26
4
S
0
27904
6.35
D
440839
D
As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.23 to $6.49. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Christian Klemt, Attorney-in-Fact
2024-02-28